2-TIP DIABETNI DAVOLASHDA YANGI USULLAR VA ULARNING SAMARADORLIGI
Keywords:
-tip diabet, SGLT2 inhibitörlari, GLP-1 agonistlari, insulin rezistentlik, metabolik sindrom, semaglutid, dapagliflozin, individual yondashuv, kardio-metabolik xavf.Abstract
Ushbu maqolada 2-tip qandli diabetni davolashda so‘nggi yillarda joriy etilgan zamonaviy terapevtik yondashuvlar, ularning molekulyar mexanizmlari va klinik samaradorligi yoritiladi. An’anaviy glyukozani pasaytiruvchi vositalarga qo‘shimcha ravishda, SGLT2 inhibitörlari, GLP-1 retseptor agonistlari va ikkilamchi metabolik targ‘ibotga asoslangan gibrid preparatlar 2-tip diabet bilan og‘rigan bemorlarning qon glyukoza nazoratini, yurak-qon tomir salomatligini va tana massasini yaxshilashda muhim o‘rin tutmoqda. Maqolada ushbu dori vositalarining klinik tadqiqotlar bilan asoslangan samaradorligi, xavfsizlik profili va ilg‘or davolash protokollaridagi o‘rni tahlil qilinadi.
References
1. Zinman B, et al. (2015). Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine, 373(22), 2117–2128.
2. Marso SP, et al. (2016). Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 375(4), 311–322.
3. Heerspink HJL, et al. (2020). Dapagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine, 383(15), 1436–1446.
4. Wilding JPH, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002.
5. Frias JP, et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515.
6. ADA Standards of Medical Care in Diabetes – 2024. Diabetes Care, 47(Supplement_1), S1–S300.
7. Davies MJ, et al. (2022). Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the ADA and EASD. Diabetologia, 65(12), 1925–1966.
8. Wanner C, et al. (2016). Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. New England Journal of Medicine, 375(4), 323–334.
9. Nauck MA, Meier JJ. (2018). Incretin-based therapies: where will we be 50 years from now? Diabetologia, 61(1), 1–6.
10. McGuire DK, et al. (2021). Cardiovascular Safety of Non-insulin Antidiabetic Drugs: Insights From Large Outcome Trials. Journal of the American College of Cardiology, 77(6), 668–679.